Regenxbio Inc. (LS:A140E0) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Closed: US$108M raised · US$9 a share · Morgan Stanley +3 Dealers: Morgan Stanley (co-lead), J.P. Morgan (co-lead), Leerink Partners (co-lead), Mizuho (co-lead) Use of proceeds: Extend cash runway into Q4 2027 and support the planned AFFINITY RISE ex-U.S. randomized-controlled trial of RGX-202 in 1H 2027 | Aug 6, 2026 |
| Limited recourse royalty bond with warrants Tranche closed: US$150M raised · Warrants at US$14.92 Buyers: Healthcare Royalty (HCRx) (up to $250 million bond; $150 million funded at closing, plus warrants for up to 268,096 shares) Use of proceeds: Extend cash runway into early 2027 and fund late-stage activities and commercial preparations | May 19, 2025 |